185 related articles for article (PubMed ID: 36854518)
1. The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma.
Pinto PC
Anticancer Res; 2023 Mar; 43(3):983-991. PubMed ID: 36854518
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma therapy: Current and new drug candidates.
Pontes O; Oliveira-Pinto S; Baltazar F; Costa M
Drug Discov Today; 2022 Jan; 27(1):304-314. PubMed ID: 34265458
[TBL] [Abstract][Full Text] [Related]
5. Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance.
Khattak M; Larkin J
World J Urol; 2014 Feb; 32(1):19-29. PubMed ID: 23297098
[TBL] [Abstract][Full Text] [Related]
6. [Targeted treatment of renal cell carcinoma, treatment caused side-effects and side-effect management].
Nagyiványi K; Géczi L
Orv Hetil; 2017 Sep; 158(38):1488-1502. PubMed ID: 28920717
[TBL] [Abstract][Full Text] [Related]
7. Dosing strategies and optimization of targeted therapy in advanced renal cell carcinoma.
Ryan CW
J Oncol Pharm Pract; 2017 Jan; 23(1):43-55. PubMed ID: 26625878
[TBL] [Abstract][Full Text] [Related]
8. Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.
Schmidinger M; Danesi R
Oncologist; 2018 Mar; 23(3):306-315. PubMed ID: 29146618
[TBL] [Abstract][Full Text] [Related]
9. Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: A proposed strategy.
Tsuchiya N
Int J Urol; 2019 Jan; 26(1):48-56. PubMed ID: 30276868
[TBL] [Abstract][Full Text] [Related]
10. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson T
Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393
[No Abstract] [Full Text] [Related]
11. Novel agents and approaches for advanced renal cell carcinoma.
Figlin R; Sternberg C; Wood CG
J Urol; 2012 Sep; 188(3):707-15. PubMed ID: 22818130
[TBL] [Abstract][Full Text] [Related]
12. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
Bilen MA; Carlisle JW; Sonpavde G
Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
[TBL] [Abstract][Full Text] [Related]
13. Current practices in the management of adverse events associated with targeted therapies for advanced renal cell carcinoma: a national survey of oncologists.
Ruiz JN; Belum VR; Creel P; Cohn A; Ewer M; Lacouture ME
Clin Genitourin Cancer; 2014 Oct; 12(5):341-7. PubMed ID: 25035283
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for renal cell carcinoma.
Fisher R; Pickering L; Larkin J
Expert Opin Investig Drugs; 2011 Jul; 20(7):933-45. PubMed ID: 21506895
[TBL] [Abstract][Full Text] [Related]
16. A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma.
Meng WS; Salgia NJ; Pham NB; Velankar KY; Pal SK
Urol Oncol; 2021 Jun; 39(6):338-345. PubMed ID: 32402767
[TBL] [Abstract][Full Text] [Related]
17. Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.
Massari F; Mollica V; Rizzo A; Cosmai L; Rizzo M; Porta C
Expert Opin Drug Saf; 2020 Oct; 19(10):1329-1338. PubMed ID: 32799582
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies.
George S; Rini BI
Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S40-4. PubMed ID: 17239283
[TBL] [Abstract][Full Text] [Related]
19. Emerging targeted therapies in metastatic renal cell carcinoma.
Matrana MR; Atkinson B; Jonasch E; Tannir NM
Curr Clin Pharmacol; 2011 Aug; 6(3):189-98. PubMed ID: 21827388
[TBL] [Abstract][Full Text] [Related]
20. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
